
News|Videos|December 7, 2020
Closing Thoughts on Research into the Induction of Fetal Hemoglobin by FTX6058
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on his closing thoughts on the research he conducted into the induction of fetal hemoglobin by FTX6058.
Advertisement
Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.
In this video, Moxham notes some closing thoughts on his research into the induction of fetal hemoglobin by FTX6058.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
2
ATTR-CM Red Flags, Treatment Evidence, and the Pharmacist's Role in Care
3
Final CLL14 Analysis Confirms Durable Benefit With Fixed-Duration Venetoclax-Obinutuzumab in Frontline CLL
4
A Paradigm Shift in Lipid Management: Highlights from the NLA 2026 Scientific Sessions Opening Session
5


































































































































